In the US, the tablet is sold under the trade name Zolinza (vorinostat). If approved, the centralized filing of this application would allow Merck Sharp & Dohme (MSD) to market this product in all 27 EU member states, as well as Iceland and Norway.
Stephen Friend, executive vice president of oncology at Merck Research Laboratories, said: “The filing of a marketing application for vorinostat in Europe reflects our ongoing commitment to bring novel anticancer agents to market worldwide. Vorinostat is one of several investigational therapies that represent an important part of the growing MSD oncology franchise, offering the potential to become an important therapeutic option for cutaneous T-cell lymphoma as well a variety of cancer tumor types.”